Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly used to treat lung cancer patients with EGFR mutations, according to new research from MD Andrerson Cancer Center. Retrospective analysis of clinical patient data suggests that beta blockers may slow or prevent the development of resistance to EGFR inhibitors.
The research, published today...
The addition of ribociclib, an inhibitor of the cell cycle, to standard hormone therapy significantly improved progression-free survival (...
In a randomized, Phase III trial led by MD Anderson researchers, the PARP inhibitor talazoparib extended progression-free survival (PFS) and...